Status:
WITHDRAWN
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Lead Sponsor:
Case Comprehensive Cancer Center
Conditions:
Pulmonary Metastatic Osteosarcoma (pOS)
Eligibility:
All Genders
5-30 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical...
Detailed Description
This study is a single-arm, open-label, proof of concept clinical trial in children, adolescent and young adult patients with unresectable pOS that have progressed, relapsed or are refractory to stand...
Eligibility Criteria
Inclusion
- Subjects may be male or female and must be equal to or greater than 5 years of age but less than or equal to 30 years of age at the time of enrollment. No large studies have evaluated the use of Natalizumab in younger pediatric patients, and Natalizumab is currently only FDA approved for adult use; for this reason, children younger than 5 years of age are excluded from this study.
- Subjects must have histologic verification of pOS.
- Subjects must have measurable pulmonary disease or pleural disease per RECIST 1.1 documented by clinical, radiographic and histologic criteria, and have progressed, relapsed or become refractory to conventional therapy.
- \-- Subjects despite having peripheral diseases elsewhere outside of pulmonary disease or pleural disease, may be eligible:
- if these diseases have failed upfront standard therapy AND
- one or two salvage therapies
- Subjects must have recovered from the acute toxic effects with ≤ Grade 1 as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 of all prior chemotherapy and immunotherapy with the exception of alopecia, anorexia, bone pain, and tumor pain prior to entering this study.
- Myelosuppressive chemotherapy: Must have adequate recovery of counts from previous treatment prior to entry onto this study.
- Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody.
- Subjects must have a performance status corresponding to a Karnofsky ≥ 50% for participants \> 16 years of age and Lansky ≥ 60 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score.
- Subjects must have normal organ and marrow function as defined below:
- Adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) ≥ 750/mcL
- Platelet count ≥ 75,000/mcL (transfusion independent)
- Hemoglobin ≥ 8.0 g/dL (may receive packed red blood cell transfusions)
- Adequate liver function defined as:
- Total bilirubin ≤ 1.5 times the upper limit of normal for age
- AST (SGOT) and ALT (SGPT) 2.5 X institutional upper limit of normal
- Serum albumin \> 2 g/dL
- Adequate cardiac function defined as:
- Ejection fraction of ≥ 50% by echocardiogram
- Subjects must have the ability to understand and the willingness to sign a written informed consent document if ≥ 18 years of age and an assent document if \< 18 years of age. If \< 7 years of age, no assent document is required.
Exclusion
- The presence of any of the following will exclude a subject from study enrollment.
- Patients with evidence of osteosarcoma outside of the lungs or pleura.
- Ongoing prior treatment toxicities \> Grade 1 according to NCI CTCAE Version 5.0 with the exception of alopecia, anorexia, bone pain and tumor pain.
- Subjects receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Natalizumab.
- Subjects currently on immunosuppressive therapy.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, liver failure, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or breastfeeding women are excluded from this study because Natalizumab crosses the placenta and can increase the risk of spontaneous abortion. There is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with Natalizumab, therefore breastfeeding should be discontinued if the mother is treated with Natalizumab.
- Female participants of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- HIV-positive subjects and HIV-positive subjects on antiretroviral therapy are ineligible because of the risk for developing a lethal infection when treated with immunosuppressive therapy.
- Participants who have or have had progressive multifocal leukoencephalopathy (PML).
- Participants whose pulmonary metastatic disease or pleural disease can be completely surgically resected.
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03811886
Start Date
December 1 2024
End Date
October 1 2026
Last Update
January 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106